Point72 Asset Management
ACAD icon

Point72 Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Point72 Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.4M Sell
2,577,916
-799,395
-24% -$19.1M 0.07% 317
2025
Q4 		$90.2M Buy
3,377,311
+1,890,954
+127% +$45.2M 0.1% 210
2025
Q3 		$31.7M Sell
1,486,357
-1,686,154
-53% -$39.9M 0.05% 383
2025
Q2 		$68.4M Sell
3,172,511
-1,475,305
-32% -$27.4M 0.13% 190
2025
Q1 		$77.2M Buy
4,647,816
+2,417,001
+108% +$43.9M 0.18% 136
2024
Q4 		$40.9M Buy
+2,230,815
New +$36M 0.09% 259
2024
Q3 		– Sell
-3,710,140
Closed -$60.3M – 1939
2024
Q2 		$60.3M Buy
3,710,140
+2,933,440
+378% +$47.3M 0.16% 172
2024
Q1 		$14.4M Buy
776,700
+383,873
+98% +$9.51M 0.03% 580
2023
Q4 		$12.3M Buy
392,827
+342,184
+676% +$8.17M 0.03% 621
2023
Q3 		$1.06M Sell
50,643
-841,283
-94% -$22.8M ﹤0.01% 1309
2023
Q2 		$21.4M Buy
891,926
+232,420
+35% +$5.17M 0.06% 369
2023
Q1 		$12.4M Sell
659,506
-456,394
-41% -$8.69M 0.04% 485
2022
Q4 		$17.8M Buy
+1,115,900
New +$17.4M 0.06% 368
2021
Q1 		– Sell
-167,100
Closed -$7.36M – 932
2020
Q4 		$8.93M Sell
167,100
-411,095
-71% -$20.4M 0.04% 465
2020
Q3 		$23.9M Buy
578,195
+379,685
+191% +$16.4M 0.12% 233
2020
Q2 		$9.62M Buy
+198,510
New +$9.53M 0.06% 348
2020
Q1 		– Sell
-671,009
Closed -$28.7M – 751
2019
Q4 		$28.7M Buy
+671,009
New +$29.2M 0.15% 196
2019
Q3 		– Sell
-1,600
Closed -$43K – 1093
2019
Q2 		$43K Sell
1,600
-389,928
-100% -$9.96M ﹤0.01% 1173
2019
Q1 		$10.5M Sell
391,528
-1,855,072
-83% -$43.3M 0.05% 387
2018
Q4 		$36.3M Buy
2,246,600
+439,600
+24% +$8.54M 0.18% 154
2018
Q3 		$37.5M Sell
1,807,000
-1,287,501
-42% -$20.3M 0.15% 184
2018
Q2 		$47.3M Sell
3,094,501
-1,262,925
-29% -$22.5M 0.19% 150
2018
Q1 		$97.9M Buy
4,357,426
+1,961,328
+82% +$54.3M 0.41% 57
2017
Q4 		$72.1M Buy
2,396,098
+1,670,898
+230% +$53.4M 0.31% 81
2017
Q3 		$27.3M Sell
725,200
-680,822
-48% -$22.1M 0.12% 208
2017
Q2 		$39.2M Sell
1,406,022
-525,178
-27% -$15.7M 0.22% 126
2017
Q1 		$66.4M Buy
1,931,200
+706,200
+58% +$24.9M 0.37% 56
2016
Q4 		$35.3M Sell
1,225,000
-846,500
-41% -$22.4M 0.25% 121
2016
Q3 		$65.9M Buy
2,071,500
+871,800
+73% +$29.6M 0.46% 40
2016
Q2 		$38.9M Sell
1,199,700
-1,023,000
-46% -$34.2M 0.27% 99
2016
Q1 		$62.1M Buy
2,222,700
+1,918,900
+632% +$41.8M 0.48% 39
2015
Q4 		$10.8M Sell
303,800
-1,708,200
-85% -$60.2M 0.09% 268
2015
Q3 		$66.5M Buy
2,012,000
+664,744
+49% +$27.7M 0.52% 38
2015
Q2 		$56.4M Sell
1,347,256
-900,044
-40% -$34.8M 0.39% 59
2015
Q1 		$73.2M Buy
2,247,300
+1,228,700
+121% +$42.2M 0.5% 39
2014
Q4 		$32.3M Buy
1,018,600
+93,600
+10% +$2.65M 0.23% 150
2014
Q3 		$22.9M Sell
925,000
-157,000
-15% -$3.67M 0.17% 163
2014
Q2 		$24.4M Buy
+1,082,000
New +$22.6M 0.16% 177

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Point72 Asset Management's ACAD Position: Q1 2026 in Review

Point72 Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 24% in Q1 2026, selling an estimated $19.1M and leaving 2,577,916 shares worth $57.4M. The position accounts for 0.07% of the portfolio, ranked #317.

Point72 Asset Management first reported a position in ACAD in Q2 2014 and has held it in 38 quarters since. The position peaked at $97.9M in Q1 2018. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Point72 Asset Management held 2,577,916 shares of Acadia Pharmaceuticals worth $57.4M as of Q1 2026.
  • Point72 Asset Management sold 799,395 Acadia Pharmaceuticals shares in Q1 2026, an estimated $19.1M.
  • Acadia Pharmaceuticals made up 0.07% of Point72 Asset Management's portfolio in Q1 2026, its #317 holding.
  • Point72 Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2014 and has held it in 38 quarters since.
  • Point72 Asset Management's Acadia Pharmaceuticals position peaked at $97.9M in Q1 2018.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.